Investor Presentation
TRX count
(000s)
NWA UTOTOO
20
10
60
50
40
30
90
80
70
0
0
6
12
18
134
Investor presentation First six months of 2022
Total RybelsusⓇ TRx volume is steadily growing in the US
RybelsusⓇ and SGLT-2i¹ uptake in the US² since respective launches
Rybelsus® TRX
SGLT-2i TRX
78
•
.
In H1, RybelsusⓇ sales account for 20% share of
growth of NAO sales
Successful RybelsusⓇ launch despite COVID-19
impacting the first year of launch
Rybelsus® TRX steadily increasing to above 60,000
Rx per week
Time since launch (weeks)
96
102
108
114
120
126
132
138
60
60
1SGLT-2i is an average of empagliflozin and canagliflozin script count. 2Rybelsus® is based on Oct 2019 focus launch. Each data points represents a rolling four-week average.
Note: NBRX: New-to-brand prescriptions; TRX: Total prescription data; Source: IQVIA Xponent, Weekly (ending 15th July 2022)
NAOView entire presentation